10-propargyl-10-deazaaminopterin

10/01/2017 - "These results indicate that pralatrexate is generally well tolerated and effective in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. "
08/01/2012 - "Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma."
01/01/2012 - "Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma."
11/26/2020 - "Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial."
10/01/2017 - "Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma."

03/01/2013 - "This paper discusses the pharmacokinetics and efficacy of pralatrexate in T-cell lymphoma in clinical trials. "
01/01/2021 - "This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile."
03/01/2013 - "Currently, the potential synergy between pralatrexate and other agents in T-cell lymphoma is being explored in a number of studies. "
09/01/2011 - "Pralatrexate has significant activity in vitro, and in early Phase I/II trials, responses were noted in patients with aggressive T-cell lymphomas. "
01/01/2021 - "Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study."

01/01/2023 - "The enhanced polyglutamylation ability of pralatrexate is associated with increased tumor cell death and ultimately improved anticancer activity. "
12/01/2022 - "Further analysis demonstrated that the reduced phosphorylation of mTOR played a significant role in the tumor cell damage caused by pralatrexate. "
12/01/2022 - "Additionally, pralatrexate at 20 mg/kg had an excellent tumor inhibitory effect with an inhibitory rate of 76.92% in vivo. "
03/01/2019 - "Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate."
11/01/2017 - "In this review, we will bring the reader up to date on the many new aspects related to pralatrexate's pharmacology, activity across the panoply of T-cell lymphoproliferative malignancies, as well as some new and emerging guidelines that are likely to improve its safety profile. "

03/01/2014 - "Clinical remission of primary aggressive CD8+ cutaneous T-cell lymphoma after pralatrexate infusion."
05/01/2021 - "also support the clinical efficacy of pralatrexate to treat advanced-stage cutaneous T-cell lymphomas, but outcomes in Japanese patients have not yet been reported. "
11/01/2018 - "Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate."
05/03/2012 - "Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma."
07/15/2017 - "Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma."

08/01/2012 - "Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study."
05/01/2021 - "We herein describe two Japanese patients with heavily-pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate."
05/01/2021 - "Pralatrexate for refractory mycosis fungoides in two Japanese patients."
08/01/2014 - "This study aimed to assess the long-term tolerability of pralatrexate alone or in combination with oral bexarotene for relapsed or refractory mycosis fungoides (MF). "
08/01/2014 - "Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides."